Exelixis (EXEL) Shares Outstanding (2010 - 2026)
Exelixis (EXEL) posted quarterly Shares Outstanding (Entity) of $253.7 million for Q2 2026, down 7.76% year-over-year from $275.0 million in Q2 2025, and down 3.35% quarter-over-quarter from $262.5 million in Q1 2026.
Analysis
Exelixis (EXEL) Shares Outstanding (2010 - 2026) Analysis & Trends
Exelixis' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $253.7 million for Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) fell 7.76% year-over-year to $253.7 million; the TTM figure through Apr 2026 stood at $253.7 million (down 7.76% YoY), while the FY2026 annual figure was $262.5 million, down 6.83% from the prior year.
- Shares Outstanding (Entity) for Q2 2026 stood at $253.7 million, down from $262.5 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $325.0 million in Q1 2023, with the low at $253.7 million in Q2 2026.
- The 5-year median for Shares Outstanding (Entity) is $295.0 million (2024), against an average of $295.6 million.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) climbed 2.24% in 2022, then decreased 10.94% in 2024.
- Exelixis' Shares Outstanding (Entity) stood at $324.0 million in 2022, then decreased by 6.53% to $302.8 million in 2023, then decreased by 5.62% to $285.8 million in 2024, then fell by 6.19% to $268.1 million in 2025, then dropped by 5.37% to $253.7 million in 2026.
- Business Quant data shows EXEL's Shares Outstanding (Entity) at $253.7 million in Q2 2026, $262.5 million in Q1 2026, and $268.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 250.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 250.81 Mn |
| Apr 3, 2026 | 258.33 Mn |
| Jan 2, 2026 | 271.57 Mn |
| Oct 3, 2025 | 268.42 Mn |
| Jul 4, 2025 | 272.58 Mn |
| Apr 4, 2025 | 278.80 Mn |
| Jan 3, 2025 | 290.03 Mn |
| Sep 27, 2024 | 285.62 Mn |
| Jun 28, 2024 | 289.22 Mn |
| Mar 29, 2024 | 300.76 Mn |
| Dec 29, 2023 | 318.15 Mn |
| Sep 29, 2023 | 315.50 Mn |
| Jun 30, 2023 | 324.21 Mn |
| Mar 31, 2023 | 324.42 Mn |
| Dec 30, 2022 | 321.53 Mn |
| Sep 30, 2022 | 322.15 Mn |
| Jul 1, 2022 | 321.12 Mn |
| Apr 1, 2022 | 319.58 Mn |
| Dec 31, 2021 | 314.88 Mn |
| Oct 1, 2021 | 315.38 Mn |